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Abstract
Protein–protein interactions are challenging targets for modulation by small molecules. Here, we propose an approach that
harnesses the increasing structural coverage of protein complexes to identify small molecules that may target protein
interactions. Specifically, we identify ligand and protein binding sites that overlap upon alignment of homologous proteins.
Of the 2,619 protein structure families observed to bind proteins, 1,028 also bind small molecules (250–1000 Da), and 197
exhibit a statistically significant (p,0.01) overlap between ligand and protein binding positions. These ‘‘bi-functional
positions’’, which bind both ligands and proteins, are particularly enriched in tyrosine and tryptophan residues, similar to
‘‘energetic hotspots’’ described previously, and are significantly less conserved than mono-functional and solvent exposed
positions. Homology transfer identifies ligands whose binding sites overlap at least 20% of the protein interface for 35% of
domain–domain and 45% of domain–peptide mediated interactions. The analysis recovered known small-molecule
modulators of protein interactions as well as predicted new interaction targets based on the sequence similarity of ligand
binding sites. We illustrate the predictive utility of the method by suggesting structural mechanisms for the effects of
sanglifehrin A on HIV virion production, bepridil on the cellular entry of anthrax edema factor, and fusicoccin on vertebrate
developmental pathways. The results, available at http://pibase.janelia.org, represent a comprehensive collection of
structurally characterized modulators of protein interactions, and suggest that homologous structures are a useful resource
for the rational design of interaction modulators.
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Introduction
Protein–protein interactions are a broad class of therapeutic and
chemical biology targets [1]. Traditionally these targets were
thought to be refractory to small molecule modulation. However,
recent efforts have led to interaction modulators that are valuable
tools in mapping signalling networks and are entering clinical trials
for therapeutic use [2]. Although natural substrates often serve as
guides for rational drug design, such information is rarely available
for protein–protein interfaces [3]. Here we attempt to provide such
a starting point through a structural analysis of known protein and
ligand binding sites. We posit that although ligands that are known
to bind to specific protein–protein interfaces are rare, examples of
ligands that bind to corresponding positions in homologous proteins
may be available. These homologous sites, and the ligands they
bind, may serve as starting points for rationally designing small
molecule modulators of protein interactions.
The physicochemical, geometric, and evolutionary properties of
ligand and protein binding sites have been extensively studied by
analyzing three-dimensional protein structures [4–6]. On average,
protein interfaces are relatively planar, more physically adaptable,
and much larger than the small, rigid, pockets that bind small
molecules [5,7]. Despite the large total surface area of protein
interfaces, a small subset of these residues, termed ‘hotspots’,
contribute disproportionately to the affinity of protein–protein
interactions [8–10]. Small molecules that target these hotspots
have been found to effectively compete against proteins in binding
events [11].
The computational methods developed for traditional rational
drug design, such as pocket detection and virtual screening, have
also been applied to identify small molecules modulators of protein
interactions. The methods are frequently adapted to the unique
properties of protein interfaces, such as their adaptivity in forming
small transient cavities that can bind small molecules [12]. This
property led to the use of molecular dynamics simulations to search
protein interfaces for transient pockets that are subsequently
targeted by virtual screening [13]. In this study, we take a
conceptually related approach that harnesses the conformational
(and chemical) space sampled by homologous members of a protein
family. The magnitude and direction of this evolutionary sampling
has been found to correlate with the conformational space sampled
physically by an individual member of a protein family [14–16].
Here, we perform a systematic analysis of structurally
characterized ligand and protein binding sites, with a central goal
of comprehensively identifying, enumerating, and describing those
positions in protein structure families where both ligands and
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proteins have been observed to bind. We first analyze the overlap
of these binding sites within protein families, characterizing the
composition and conservation of these ‘bi-functional’ positions,
and identifying the families in which they are more or less
prevalent than expected by chance. Next, we describe protein–
protein and protein–peptide interactions for which small mole-
cules were observed to bind at corresponding or homologous
positions in other protein structures. Finally, we describe known
interaction modulators recovered by the analysis, and illustrate its
predictive utility by suggesting structural mechanisms for the
observed effects of three small molecules.
Results
Ligand and protein binding sites
We began by assembling a comprehensive list of protein and
ligand binding sites. Protein–protein (inter-molecular domain–
domain, intra-molecular domain–domain, and domain–peptide)
binding sites were obtained from PIBASE (v200808) [17], based
on domain boundaries and classifications from SCOP (v1.73)
[18] (details in Materials and Methods). Peptide binding sites
were included in the analysis because the structures of protein
complexes are often solved with only the peptides that mediate
the interaction, rather than the full-length protein. Ligand
binding sites were obtained from LIGBASE [19], and mapped
onto SCOP domains using family alignments from the ASTRAL
compendium [20]. Binding sites that shared more than 90% of
their corresponding alignment positions were grouped together
and a representative was chosen randomly, yielding a final
dataset of 35,168 ligand binding sites, 2,332 peptide binding sites,
12,015 inter-molecular domain interfaces, and 4,290 intra-
molecular domain interfaces, for all of which the structure is
known (Table S3). This redundancy removal procedure (Mate-
rials and Methods) partially corrects the human bias in structural
coverage of proteins, protein complexes, and protein-ligand
complexes. Other aspects of bias can not be corrected and
therefore affect our observations; For example, the analysis is
limited to those proteins, ligands, and complexes that have been
structurally characterized.
Protein families with overlapping ligand and protein
binding sites
We first quantified the extent and significance of overlap
between all ligand and protein binding sites observed in each
protein family. The binding sites were mapped onto alignments of
domain families obtained from the ASTRAL compendium [20]
(Fig. S1B). This mapping procedure implicitly accounts for
redundant structures, as multiple structures of the same binding
site do not contribute any additional positions beyond those
protein-binding or ligand-binding positions identified by the first
structure. Of the 2,619 families that bind proteins, 1,028 also bind
small molecules, and 736 of these have at least 5 bi-functional
positions (Table S1). The overlap of ligand and protein binding
sites within each family was quantified using the numbers of
alignment positions at which ligands (nl ), proteins (np), or both
ligands and proteins (nb) were bound, as well as the number of
solvent-exposed positions (ns).
Overlap(family)~
nbns
nlnp
ð1Þ
An alignment position was considered solvent-exposed if at least
one of the domains in the family had a residue with side-chain
solvent exposure of greater than 7% at that position (MOD-
ELLER v9.4 [21]). The statistical significance (Fisher’s exact one-
tailed p-value) of the observed overlap for each family was assessed
against a null model in which the ligand and protein binding site
positions are randomly and independently placed at solvent-
exposed positions (R v2.5.1, http://r-project.org). We identified
197 families with significantly more (right-tail p-valv0.01), and
113 families with significantly fewer (left-tail p-valv0.01), bi-
functional positions than expected by chance (Fig. 1A, Table S2).
These two sets of families exhibit differences in the distribution of
functions as defined by SUPERFAMILY [22] (Fig. S1D). The
significance of the function propensity values were estimated by a
non-parametric bootstrap sampling procedure to compute 95%
confidence intervals (Table S4, Materials and Methods). Families
with significantly less overlap (p-valv0:01) than expected by
chance were enriched in Metabolism and depleted in Regulation
(a~0:05). In contrast, families with significantly more overlap (p-
valv0:01) than expected by chance were depleted in Metabolism
and enriched in Intracellular processes (a~0:05). For example, ten
of the overlapping families are involved in signal transduction
compared to none of the non-overlapping families.
Composition and conservation of bi-functional positions
We next asked whether the chemical or evolutionary properties
of bi-functional positions were different from other positions that
were part of only ligand or protein binding sites (mono-functional)
or solvent-exposed. The propensities of each amino acid residue at
mono-functional and bi-functional positions were calculated
relative to all exposed residues, and their significance estimated
by a bootstrap resampling procedure (Fig. 1B, Table S5, Materials
and Methods). The magnitudes of these propensities are within the
range reported in previous binding site analyses [4,23]. The
propensity of residue types that exist at the bi-functional positions
are generally intermediate between those of ligand-only and
protein-only positions, although they are more similar to the
ligand-only positions (Fig. 1B). In particular, bi-functional
positions have a higher propensity of tryptophan, histidine, and
phenylalanine residues relative to both protein-binding positions
and solvent exposed residues. In addition, bi-functional positions
Author Summary
Proteins function through their interactions with other
biological molecules, including other proteins. Often times,
these interactions underlie cellular processes that go awry
in disease. Therefore, modulating these interactions with
small molecules is an active area of research for new drugs
to treat diseases and new chemical tools to dissect cellular
interaction networks. However, targeting protein–protein
interactions has proven to be more challenging than the
typical drug targets found on individual proteins. Here, we
present a computational approach that aims to help in this
challenge by identifying regions of protein–protein
interfaces that may be amenable to targeting by small
molecules. Through a comprehensive analysis of all known
protein structures, we identify closely related proteins that
in one case bind a protein and in another case bind a small
molecule. We find that a significant number of protein–
protein interactions occur through surface regions that
bind small molecules in related proteins. These ‘‘bi-
functional’’ positions, which can bind both proteins and
ligands, will serve as an additional piece of structural
information that can aid experimentalists in developing
small molecules that modulate protein interactions.
Overlapping Ligand and Protein Binding Sites
PLoS Computational Biology | www.ploscompbiol.org 2 February 2010 | Volume 6 | Issue 2 | e1000668
have a higher propensity for tyrosine, and slightly lower
propensities for alanine, isoleucine, leucine, and valine, than
either mono-functional or solvent-exposed positions.
Bi-functional positions are also significantly less conserved
than mono-functional or solvent exposed positions, as measured
by an entropy-based conservation score (Fig. 1C) as well as a
simple count of residue types (Fig. S1E). This lower conservation
was considered statistically significant (p-valv2:2 x 10{16) by
both Kolmogorov-Smirnov and Mann-Whitney tests (Materials
and Methods). Although it is difficult to precisely identify the
reason for the lower conservation of bi-functional positions, one
possible explanation is related to the definition of these
positions. We identified bi-functional positions because they
participate in different functions – ligand binding and protein
binding – in different family members. These different functions
might require different residue type compositions, resulting in a
lower conservation score for these positions. We also observed
minimal, although statistically significant (p-valv2:2 x 10{16),
differences in conservation between mono-functional and
solvent-exposed residues: ligand-only positions were more
conserved than all exposed residues, which in turn were more
conserved than protein-only positions. The small magnitude of
the difference in conservation between mono-functional and all
exposed residues is in agreement with previous findings that
conservation alone is of minimal predictive use for the
identification of binding sites [6].
Protein–protein interactions with overlapping ligand
binding sites
Having established that ligand and protein binding sites often
overlap within protein families, we aimed to determine the utility
of known ligand binding sites for targeting particular protein–
protein interactions. The ligand binding sites were mapped onto
individual domain–domain and domain–peptide interfaces, using
ASTRAL alignments as described earlier (Fig. S1C). The overlap
between each ligand binding site and protein interface was
characterized by the fraction of interface residues aligned to ligand
binding site residues.
Overlap(Interface,Ligand)~
jInterface\Ligandj
jInterfacej ð2Þ
When the ligand binding site aligned to both sides of a domain–
domain interface, the larger of the two overlap fractions was used
as the overlap score.
The ligand binding site coverage of each protein–protein
interface was summarized using two scores. First, a maximal
overlap score was used to quantify the maximum overlap observed
by any ligand for the protein–protein interface. Second, a
cumulative overlap score was computed by simultaneously aligning
all homologous ligand binding sites onto each protein–protein
interface and calculating the fraction coverage. This procedure is
conceptually related to fragment-based drug discovery techniques,
such as tethering [24].
The behavior of these overlap scores was examined as a
function of the sequence identity between the ligand binding site
and the corresponding positions in the interacting proteins (Fig. 2,
S2). As expected, the coverage of interfaces was reduced at higher
thresholds of sequence identity (Fig. 2A, 2B), and the distributions
of cumulative overlap scores (Fig. S2G, S2H, S2I) exhibit a higher
interface coverage than the corresponding distributions of
maximum overlap scores (Fig. S2A, S2B, S2C). In addition, the
domain–peptide interfaces have higher binding site overlaps
(Fig. 2B), on average, than domain–domain interfaces (Fig. 2A).
This observation is likely due to the smaller sizes of domain–
Figure 1. The overlap of ligand and protein binding sites
within protein families. (A) The distribution of overlap scores (Eqn 1)
is shown for all families that bind both ligands and proteins (grey;
n = 1,028), and the subsets of families with a statistically significant
overlap (pv0.01; solid; n = 197) or non-overlap (pv0.01; dashed;
n = 113). The highest overlap score observed is 10.83 (not shown). (B)
The residue type propensity (Eqn 3) and (C) conservation (Eqn 4) at
alignment positions that bind both ligands and proteins (black;
n = 102,436), bind ligands (cyan; n = 46,610), bind proteins (orange;
n = 491,723) in comparison to all solvent-exposed residues (grey;
n = 1,147,882). The statistical significance of the residue propensities
was estimated by a bootstrap resampling procedure (Table S5).
doi:10.1371/journal.pcbi.1000668.g001
Overlapping Ligand and Protein Binding Sites
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peptide interfaces, which are thus more readily covered by small
molecule binding sites.
Although the analysis suggests that most interfaces do not have a
homologous ligand binding site, as seen by the main peak over an
interface overlap of 0 (Fig. 2C), there are a significant number of
interfaces for which overlapping homologous ligand binding sites
do exist. In particular, a significant number of protein interfaces
overlap with homologous ligand binding sites of greater than 30%
sequence identity, previously determined to be a reliable threshold
for homology transfer of ligand binding sites [25].
The systematic alignment of ligand binding sites onto protein
interfaces generates a dataset useful for two primary purposes.
First, it serves as a comprehensive collection of structurally
characterized interaction modulators, in the cases where the ligand
binding domain is identical to the sequence involved in the protein
interaction (Table 1). Second, it serves as a set of predicted
interaction modulators, where the ligand binding site itself is
highly similar to the corresponding region in the target interaction,
but the overall domain is only homologous, rather than identical
(Table S6).
Recovery of known interaction modulators
To validate the accuracy of the mapping method, we checked
whether known protein interaction modulators were recovered by
the method. Indeed, all but one of the modulators discussed in a
recent review article [2] were identified by the method: Interleukin-
2 – Interleukin-2 receptor (PDB 2ERJ:A,D; 1PY2:FRH), MDM2–
p53 (1T4F:M,P; 1T4E:DIZ), HPV E2–E1 helicase (1TUE:A,B;
1R6N:434), ZipA–FtsZ (1F47:A,B; 1Y2F:WAI), and TNF-a
homotrimer (2TNF; 2AZ5:307). The interaction between Bcl-X–
BAD (PDB 2BZW) was missed by our analysis because the ligand
bound structure (2YXJ:N3C) was published too recently to be
classified in the current SCOP domain database. The nearly
complete recovery of known modulators suggests that the binding
site data used in the analysis and the procedure used to map them
operated correctly. We present additional examples of ligand
binding sites that overlap interfaces to demonstrate the diversity of
interactions for which ligand binding has been observed (Table 1).
Predicted interaction modulators
Having established the accuracy of the binding site mapping, we
next examined the results for their predictive utility in identifying
small molecule modulators of protein interactions. Those ligand
binding sites that mapped with a high sequence identity, in the
context of different protein sequences, represent high confidence
predictions where ligand binding may occur (Table S6). This kind
of prediction is an extension of the widely used homology-transfer
concept in protein function annotation [25].
Ligand binding sites that overlap protein interfaces
The ligands identified in the analysis fell into four broad
categories based on the kinds of protein–protein interactions that
Figure 2. Ligand-protein binding site overlap observed at protein–protein interactions as a function of sequence identity. The
maximum observed ligand binding site overlap (y-axis) for (A) inter-molecular domain–domain and (B) domain–peptide interactions, as a function of
the ligand binding site sequence identity (x-axis). The densities in these plots are represented by colors that range from yellow (no density) to blue
(maximum density). The (C) maximal and (D) cumulative overlap profile is shown at a minimum ligand binding site identity threshold of 30% for inter-
molecular (black), intra-molecular (orange) domain–domain, and domain–peptide (cyan) interactions. Tick marks indicate interfaces that exhibit a
particular level of interface coverage. The overlap score refers to the fraction of interface residues aligned to ligand binding site residues (Eqn 2).
doi:10.1371/journal.pcbi.1000668.g002
Overlapping Ligand and Protein Binding Sites
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they overlapped (Table 1, S6). The most frequently observed
category were synthetic enzyme inhibitors that overlapped with
the interfaces between enzymes and their protein or peptide
inhibitors. These interactions include carboxypeptidase, ribonu-
clease, trypsins, coagulation factors, and their protein inhibitors
(Fig. 3A). The high number of ligands identified in this class is not
surprising, as enzyme–inhibitor complexes are among the most
extensively structurally characterized and targeted by synthetic
inhibitors.
A related group of ligands overlapped with the interface of an
enzyme and its natural protein or peptide substrate. This class
includes ligands that bound at signaling complexes such as
MDM2–p53, farnesyltransfrease–h-ras, and histone acetyltrans-
ferase–p53. An example that is used therapeutically are HIV
protease inhibitors bound at the protease dimer in place of its
peptide substrate (Fig. 3B). We also include enzyme homodimers
in this group, such as the transketolase and the ornithine
decarboxylase homodimers (Table S6).
A third class of ligands overlapped with the interface of
structural or regulatory protein–protein interactions. These ligands
include natural toxins, such as kabiramide C bound at the actin–
gelsolin interface (Fig. 3C) and fusicoccin bound at the interface of
14-3-3 proteins (Fig. 4B). This class also includes synthetic
compounds such as ajulemic acid that bound at the interface of
peroxisome proliferator activated recpetor gamma (PPARG) and
the LXXLL coactivator (Table 1).
The fourth group of ligands were transferred from structures
where they were present at domain interfaces. Although it is
difficult to predict the effect of these ligands on the target interface,
this group of ligands may be more likely to sterically complement
protein interfaces than ligands in the other groups, which more
likely sterically hinder protein interactions. This group includes
elaidoylamide bound at the homodimeric interface of agkistrodo-
toxin Phospholipase A2 (PDB 1RGB), and bepridil bound at the
interface of Troponins C and I (1LXF; Fig. 3D). Ligands in this
class may be of potential use for designing chemically induced
dimerization systems [26]. This technique relies on the ability of
particular small molecules, such as Rapamycin and FK506, to
simultaneously bind two proteins, and has been extensively used to
study and control cell signaling processes. This group of ligands
also slightly overlaps with the second group, as HIV protease
inhibitors bind at the homodimeric protease interface (Fig. 3B).
Natural ligands such as ATP, GTP, GNP also often bind at
domain interfaces.
Table 1. Examples of ligand binding sites that align to protein–protein interfaces with identical or nearly identical sequences.
Sequence identity
Protein interaction Ligand Overlap bind site domain
Enzyme–protein inhibitors
1oo9:A,B (d) MMP-3 Catalytic Domain – N-TIMP-1 1caq:DPS 71% 100% 100%
1taw:A,B (d) Bovine trypsin – appi 1o2h:CR3 81% 100% 100%
1a8k:A,C (p) HIV-1 protease – ca-p2 analog 1mrw:K57 100% 100% 100%
1bzh:A,I (p) Protein-tyrosine-phosphatase 1b – inhibitor 1g7f:INZ 100% 100% 100%
1uk4:B,H (p) SARS proteinase 3clpro – peptide inhibitor 2alv:CY6 100% 100% 99%
1e8n:A,I (p) Prolyl oligopeptidase – peptide 1h2y:ZPR 80% 100% 100%
1rgb:A,B (d) Phospholipase A2 homodimer 1rgb:ELD (*) 100% 100% 100%
Enzyme–protein substrates
1m9d:A,D (d) Cyclophilin A – HIV Gag 1nmk:SFM 100% 100% 100%
1iid:A,O (p) N-myristoyltransferase – glyaskla 2nmt:MIM 100% 100% 100%
2bgn:C,Y (p) Dipeptidyl peptidase iv – HIV-1 tat peptide 2ajl:JNH 100% 100% 100%
1kzp:A,C (p) Protein farnesyltransferase – k-ras4b peptide 1n94:TIN 100% 100% 98%
1q2d:A,B (p) Histone acetyltransferase GCN5 – p53 peptide 1m1d:LYX 88% 100% 99%
1tjk:A,I (p) Group II Phospholipase A2 – FLSTK 1fv0:9AR 86% 100% 99%
Regulatory or structural interaction
1g73:A,D (d) XIAP - BIR3 2opy:CO9 100% 100% 91%
1h1v:A,G (d) Actin – gelsolin 1qz5:KAB 88% 100% 100%
2erj:A,D (d) Interleukin 2–receptor 1py2:FRH 55% 100% 97%
1b6c:C,D (d) TGF-b receptor – FKBP12 1bl4:AP1 76% 95% 99%
1rdt:D,E (p) PPARG – LXXLL motif coactivator 2om9:AJA 100% 100% 99%
1mxl:C,I (d) Cardiac troponin C–troponin I 1lxf:BEP (*) 60% 100% 100%
1g3f:A,B (p) SMAC Diablo – XIAP BIR-3 domain 1tfq:998 100% 100% 100%
1lcj:A,B (p) Lck SH2 domain – phosphotyrosyl peptide 1fbz:CC1 100% 95% 99%
1t4f:M,P (p) Mdm2 – p53 peptide 1t4e:DIZ 88% 100% 100%
1f47:A,B (p) ZipA – FtsZ fragment 1y2f:WAI 71% 100% 95%
The overlap (Eqn 2) between each ligand and protein interface is shown along with the sequence identity of the ligand binding site and the full-length domain
sequence. (d) refers to inter-molecular domain–domain, (p) refers to domain–peptide interactions, and (*) indicates ligands that were present at domain interfaces.
doi:10.1371/journal.pcbi.1000668.t001
Overlapping Ligand and Protein Binding Sites
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Another class of protein complexes with overlapping homolo-
gous ligand binding sites are antibody–antigen complexes. These
overlaps are an expected result of the diversity of the comple-
mentary-determining regions of immunoglobulins that enable
binding to virtually all proteins and small molecules.
The ligands that mapped to intra-molecular domain interfaces
included natural ligands such as ATP, GTP, and Heme groups, as
well as synthetic and natural toxins such as the Pulvomycin and
Kirromycin antibiotics (Table S7). Since we focus on direct
modulators of protein–protein interactions, we will not discuss
these ligands. However, ligands that bind at intra-molecular
domain interfaces may serve as logical switches in cellular
signaling networks [27].
Although we observed overlaps that occur in a variety of
functional classes, they can all contribute towards a structural
understanding of bi-functional positions. Irrespective of the natural
or synthetic source of the small molecule, or the particular
functional class of protein interaction, the resulting overlaps are
structurally informative for understanding what makes particular
interface regions amenable to targeting by small molecules. This
point can be further clarified by considering the known
modulators of protein interactions that we used to test the fidelity
of our mapping procedure. Although these examples involve
synthetic small molecules, they have been extensively character-
ized structurally to understand what makes their particular binding
sites amenable to targeting by small molecules [2]. Ignoring these
examples because of their synthetic source would discard useful
structural information.
Predicting structural mechanisms for the observed
effects of small molecules
The results also suggest possible structural mechanisms for the
observed effects of small molecules. We will describe three such
examples, each from a different ligand class: sanglifehrin A,
bepridil, and fusicoccin. Sanglifehrin A is an immuno-suppressant,
synthesized by an Actinomycetes species, that has been observed to
reduce HIV-1 virion production [28]. Our structural analysis
found that its binding site on cyclophilin A [29] overlapped
completely with the complex formed by cyclophilin A and the
HIV capsid [30] (Fig. 4A). This overlap suggests that sanglifehrin
A competes with the HIV protein for interaction with cyclophilin
A. This prediction is in agreement with biochemical evidence that
describes a reduction in virion production by sanglifehrin A
through a cyclophilin-dependent mechanism [28].
Fusicoccin is a toxin, synthesized by the fungus Fusicoccum
amygdali, that disrupts protein interactions mediated by plant 14-3-
3 proteins [31]. Here we observed that its ligand binding site is
nearly conserved in mammalian 14-3-3 proteins and overlaps with
the 14-3-3-f–Seretonin N-acetyltransferase and 14-3-3-f–R18
peptide interfaces (Table S6, Fig. 4B). This high level of binding
site similarity suggests that fusicoccin also modulates animal 14-3-3
interactions. In fact, this modulation has been observed experi-
mentally, with fusicoccin used as a tool to disrupt 14-3-3
Figure 3. Small molecule binding sites overlapped with four
broad classes of protein–protein interfaces. (A) Enzyme – protein
inhibitors: eg, 39-phosphothymidine (39–59)-pyrophosphate adenosine
39-phosphate (PDB 1U1B:PAX) overlapped with the ribonuclease
(orange, 2Q4G)–inhibitor (purple, 2Q4G) interface. (B) Enzyme–protein
substrate: eg, Kni-577 (cyan, 1MRW:K47) bound to the HIV-protease
dimer (grey backbone, 1MRW:A,B; orange, 1A8K:A,B) at the same
positions as its peptide substrate (purple, 1A8K:C). (C) Structural or
regulatory interfaces: eg, kabiramide-C (cyan, 1QZ5:KAB) bound to Actin
(grey backbone, 1QZ5:A; orange, 1H1V:A) at the same position as
Gelsolin (purple, 1H1V:G). (D) Several ligands complemented protein
interfaces: eg, bepridil (cyan, 1lxf:BEP) bound at the interface between
troponin C (orange, 1LXF:C) and troponin I (purple, 1LXF:I). Figure
produced by PyMOL (http://pymol.org).
doi:10.1371/journal.pcbi.1000668.g003
Figure 4. Overlapping binding sites suggest structural mechanisms for observed small molecule effects. (A) Sanglifehrin (cyan, PDB
1NMK:SFM) binds to cyclophilin A (grey, 1NMK; orange, 1AK4:A) at the same position that binds the HIV Gag capsid protein (purple, 1AK4:D). (B)
Fusicoccin (cyan, 1O9E:FSC) binds to a region of the plant 14-3-3 protein (grey, 1O9E) that is homologous to the 14-3-3-f (orange, 1A38:A) binding
site for phosphopeptides (purple, 1A38:P). (C) Bepridil (cyan and blue, 1LXF:BEP) binds to Troponin C (grey, 1LXF:C) at positions that are homologous
to the calmodulin (orange, 1K93:D) interface for anthrax edema factor (purple, 1K93:A). Troponin C aligns to both EF-hand motifs in calmodulin: The
binding site aligned with EF-motif 2 (cyan) exhibits greater overlap with the anthrax edema factor interface than EF-motif 1 (blue).
doi:10.1371/journal.pcbi.1000668.g004
Overlapping Ligand and Protein Binding Sites
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interactions involved in early left-right developmental patterning
in Xenopus [32].
Bepridil is an FDA-approved calcium channel blocker that was
until recently used to treat refractory angina. Recently it was found
to inhibit the cellular entry of two anthrax toxin components: the
edema and lethal factors [33]. Here we observed that the troponin
C binding site for bepridil [34] transfers with high sequence
identity to the calmodulin–anthrax edema factor interface [35].
The ASTRAL family alignment transferred the binding site to the
first calmodulin EF-hand that is not directly in contact with the
edema factor. In this alignment, the binding site overlap is
minimal (1 of 46 protein interface residues; Table S6, Fig. 4C) and
occurs at the periphery of the interaction. However, upon
visualization, it was found that the second EF-hand also aligns
well with troponin C, and in this alignment the bepridil binding
site directly overlaps with the edema factor interface (Fig. 4C).
This alignment suggests that bepridil may disrupt the calmodulin–
edema factor interaction by binding to calmodulin. This
hypothesis, based on structural data alone, is in agreement with
experimental findings that describe reduction in the lethality of
edema factor by bepridil [33].
Discussion
We presented a systematic analysis of protein structure families
that identified bi-functional positions that bind both small
molecules and proteins (Fig. 1, S1; Table S1, S2, S3). These
positions were found to be less evolutionary conserved, and exhibit
a different amino acid propensity, than mono-functional or other
solvent exposed residues (Fig. 1, S1; Table S4, S5). Families with
significantly more bi-functional positions than expected by chance
were functionally enriched in intracellular processes and depleted
in metabolism; families with fewer bi-functional positions were
functionally enriched in metabolism and depleted in regulation
(Table S4, Fig. S1D). Mapping ligands onto protein interactions
by homology transfer (Fig. 2, S2) identified known (Table 1; Fig. 3)
and predicted modulators of interactions (Table S6,S7), that fell
into four broad categories. We illustrated the utility of the results
by suggesting structural mechanisms for the observed effects of
three small molecules (Fig. 4). We will now discuss future
extensions to the method and its utility for modulating protein
interactions by small molecules.
Our results suggest that structural data might be harnessed in a
comparative fashion to characterize small molecules that target
protein-protein interactions. This approach is complementary to
recent computational studies that characterize known modulators
of protein interactions [36] and predict small molecule mimics of
interacting peptide motifs [37].
This preliminary analysis can be extended in several ways to
overcome limitations inherent to the current implementation.
First, the comparative basis of the method relies on the availability
of homologous ligand-bound structures. Although the structural
coverage of protein–ligand and protein–protein complexes
continues to increase, homologous ligand binding sites are not
available for the majority of protein interactions (Fig. 2, Table S3).
This coverage can be improved by transferring ligand binding sites
based solely on local structural similarity, rather than full-length
domain similarity, as was done here. Several tools have been
developed to identify local structure similarities and can be directly
applied to the mapping of ligand binding sites onto protein
interfaces [38–40].
Second, comparing the bi-functional positions to hotspot
residues, that disproportionately contribute to the free energy of
protein interactions, will illuminate their biophysical role [9].
Previous analysis found that hotspots are enriched in tryptophan,
arginine, and tyrosine [9]. The bi-functional positions we
characterize here also exhibit a strong enrichment of tyrosine
and tryptophan, although arginine abundance is similar to the
background of all solvent exposed positions (Fig. 1B). The bi-
functional positions also exhibited significantly lower conservation
than mono-functional or exposed residues (Fig. 1C). This is in
contrast to hotspot residues where previous analysis has shown
equivalent or slightly higher conservation than the rest of the
protein surface [41]. In addition to collections of alanine scanning
mutagenesis results [42], several computational techniques have
been developed to predict hotspots [41,43,44]. Direct comparison
of these datasets to bi-functional positions will help characterize
their biophysical role.
Finally, although we have focused on ligands that may directly
modulate, by complementing or sterically competing with,
protein–protein interactions, another relevant class of interactions
is allosteric regulation. Allosteric control refers to signal propaga-
tion between two distal binding sites through a network of residues
that traverses a protein [45]. A portion of the ligand binding sites
we found to directly overlap protein interactions may reflect
allosteric sites, binding at which regulates a distal site. For
example, a ligand designed to bind to the homodimeric interface
of caspase-1 was found to exert allosteric control over the distal
catalytic site [46]. A second potential source of allosteric
interactions in our analysis is the set of 113 families that exhibited
significantly less overlap than expected between ligand and protein
binding sites. Further analysis should illuminate whether this
observed separation between ligand and protein binding sites
reflects the distal action of allosteric signaling.
Designing small molecule modulators of protein–protein
interactions
We observed that several small molecule compounds, originally
designed for traditional medicinal chemistry targets such as
enzyme active sites, in fact target protein interfaces. These include
several FDA-approved drugs, such as bepridil that binds at the
interface between Troponins C and I, and HIV protease inhibitors
that bind at the dimer interface. Although these examples involve
fairly small protein interfaces, this observation suggests that
protein–protein interactions are not completely novel targets for
medicinal chemistry, and that the chemical, biophysical, and
computational experience that has been developed in traditional
rational drug design may also be applicable to interaction targets.
As protein interaction networks are resolved with greater
accuracy and coverage [47], small molecules become important
perturbation tools to examine their functional significance. In
addition, a therapeutic application that is becoming increasingly
relevant is the targeting of host–pathogen protein interactions,
which have been the subject of recent investigations using high-
throughput experimental [48,49] and computational [50,51]
methods. These interactions may be a valuable alternative to
traditional targets for the increasingly difficult challenge of
antibiotic development [52,53]. We expect our results, available
in PIBASE (http://pibase.janelia.org), to serve as a structural
resource to aid in the rational design of small molecule modulators
of protein–protein interactions.
Materials and Methods
Obtaining protein and ligand binding sites
Residues in domain–domain and domain–peptide binding sites
were obtained from PIBASE v200808 [17] based on domain
boundaries and classifications from SCOP v1.73 [18]. Peptides
Overlapping Ligand and Protein Binding Sites
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were defined as those chains at least 5 amino acid residues long
that were not classified by SCOP or were classified in the ‘‘peptide
or fragment’’ SCOP class. Binding sites were defined as residues
containing at least one non-hydrogen atom within 5 A˚ of the
interacting domain or peptide. Domain–domain interfaces were
filtered using a threshold of at least 500 inter-atomic contacts at a
distance threshold of 5A˚ (*500 A˚2 buried surface area), to remove
small interfaces that are often crystallographic artifacts. A
minimum domain participation of 5 residues was also imposed
on domain–peptide interactions to remove small interfaces. This
procedure identified 24,717 inter-molecular domain–domain,
13,228 intra-molecular domain–domain, and 6,911 domain–
peptide interactions involving 2540, 1485, and 534 domain
families, respectively.
Ligand binding sites were obtained from LIGBASE [19],
defined as residues with at least one non-hydrogen atom within 5A˚
of the ligand. The analysis was restricted to PDB HETERO
groups with molecular weights between 250–1000 Daltons, as this
range removes crystallographic buffers and small ions present in
many PDB entries, and also encompasses most orally administered
drugs. MDL and CIF formatted descriptions of the ligand
structures were obtained from the MSD Ligand Chemistry
dictionary [54]. This procedure identified 39,085 binding sites
on domains from 1,131 families.
Removing redundant binding sites
Redundant binding sites were identified by single-linkage
clustering of binding sites that shared more than 90% of their
residues as measured by: (alignment positions shared by the two
binding sites)/(positions in either binding site). This reduced the
number of ligand binding sites from 39,085 to 35,168; peptide
binding sites from 4,937 to 2,332; inter-molecular domain
interfaces from 40,791 to 12,015, and intra-molecular domain
interfaces from 17,863 to 4,290. The redundancy removal was
performed with respect to the alignment positions, rather than
amino acid sequence identity, because the binding site projection
procedure relied on the alignment positions. This redundancy
removal procedure aimed to reduce the effect of PDB bias in
structural coverage of proteins, protein complexes, and protein-
ligand complexes.
Computing alignment position properties
The propensity of residue types in each class of position (ligand-
only binding, protein-only binding, or bi-functional) was computed
relative to all solvent exposed positions by counting the frequency
of the 20 standard amino acid residue types:
propensity(aminoacidi)~
ntype(i)
ntype
=
nexposed (i)
nexposed
ð3Þ
Residue types that occur more frequently at a particular binding
site type than in all solvent exposed positions receive a propensity
score of greater than 1, while less frequently occurring types
receive a score of less than 1. The statistical significance of the
propensity values was estimated by a bootstrap resampling
procedure to compute 95% confidence intervals, implemented in
R (http://R-project.org). Propensity values were considered
significant (a~0:05) if the corresponding 95% confidence interval
did not include the value of 1 [23].
The conservation of each alignment position was quantified
using two scores. The first was simply the number of residue types
that occurred at the position. The second was a Shannon entropy-
like score that captured how non-uniform the distribution of
residue type frequencies was at the position.
conservation(position)~1{
X20
i~1
naa(i)
nall
log20
naa(i)
nall
ð4Þ
Alignment positions that contain only one kind of amino acid
residue receive a conservation score of 1, while those with a
uniform distribution of residue types receive a score of 0. The
distributions of conservation scores for each kind of alignment
position (bi-functional, ligand-only, protein-only, or all exposed
residues) were compared using the Kolmogorov-Smirnov and
Mann-Whitney tests, as implemented in R (http://R-project.org).
Computing function propensities
Each family was assigned one of seven broad functions by
SUPERFAMILY [22]: General, Information, Metabolism, Not
Annotated, Other, Extracellular processes or Intracellular process-
es. The function propensities of families with significantly greater
or fewer bi-functional positions than expected by chance were
computed relative to the frequency of functions in all families.
propensity(set,funci)~
nset(funci)
nset
=
nall(funci)
nall
ð5Þ
Functions that occur more frequently in a particular set of
families than in all families, receive a score of greater than 1. The
significance of the function propensity values was estimated by a
non-parametric bootstrap resampling procedure to compute 95%
confidence intervals, implemented in R (http://R-project.org).
Propensity values were considered significant (a~0:05) if the
corresponding 95% confidence interval did not include the value
of 1.
Supporting Information
Table S1 Summary of protein and small molecule binding sites
in families of protein structures. The numbers of protein families
with at least 5 bi-functional positions are shown for each kind of
protein interface. Bi-functional positions refer to alignment
positions that bind both small molecules (250–1000 Da) and
proteins.
Found at: doi:10.1371/journal.pcbi.1000668.s001 (0.03 MB PDF)
Table S2 The ten families with the most significantly (p,0.01)
higher or lower number of bi-functional positions than expected
by chance. Bi-functional positions refer to alignment positions that
bind both small molecules (250–1000 Da) and proteins. The
significance of the overlap (Text Eqn 1) is assessed by the Fisher
exact test (http://r-project.org).
Found at: doi:10.1371/journal.pcbi.1000668.s002 (0.04 MB PDF)
Table S3 Summary of protein interactions and their overlap
with aligned ligand binding sites from homologous structures. The
numbers of protein interfaces with at least 20% cumulative or
maximal overlap with homologous ligand binding sites are shown
for each kind of protein interface. The overlap score refers to the
fraction of interface residues aligned to ligand binding site residues
(Text Eqn 2).
Found at: doi:10.1371/journal.pcbi.1000668.s003 (0.03 MB PDF)
Table S4 The function propensities of families with significantly
(p,0.01) higher or lower number of bi-functional positions than
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expected by chance. Bootstrap resampling was performed to
compute 95% confidence intervals of the function propensities
(Text Eqn 5). Propensities are considered significant (asterisk) at
the alpha = 0.05 level if their confidence intervals do not include
the value 1.
Found at: doi:10.1371/journal.pcbi.1000668.s004 (0.03 MB PDF)
Table S5 The residue type propensity at alignment positions
that bind both ligands and proteins, bind ligands, or bind proteins
in comparison to all solvent-exposed residues. Bootstrap resam-
pling was performed to compute 95% confidence intervals (CI) of
the residue type propensities (Text Eqn 3). Propensities are
considered significant (asterisk) at the alpha = 0.05 level if their
confidence intervals do not include the value 1.
Found at: doi:10.1371/journal.pcbi.1000668.s005 (0.03 MB PDF)
Table S6 Examples of ligand binding sites that align to
protein–protein interfaces with a high sequence similarity. The
overlap (Text Eqn 2) between each ligand and protein interface is
shown along with the sequence identity of the ligand binding site
and the full-length domain sequence. (d) refers to inter-molecular
domain–domain interactions, (p) refers to domain–peptide
interactions, and (*) indicates ligands that were present at domain
interfaces.
Found at: doi:10.1371/journal.pcbi.1000668.s006 (0.04 MB PDF)
Table S7 Examples of ligand binding sites that align to intra-
molecular domain–domain interfaces. The overlap (Text Eqn 2)
between each ligand and domain interface is shown along with the
sequence identity of the ligand binding site and the full-length
domain sequence.
Found at: doi:10.1371/journal.pcbi.1000668.s007 (0.03 MB PDF)
Figure S1 Protocol for quantifying binding site overlap,
functional, and evolutionary properties. (A) Ligand and protein
binding sites obtained from LIGBASE and PIBASE, respectively,
were mapped onto domain family alignments from the SCOP
ASTRAL compendium. (B) The square labeled A is a cartoon
representation of a protein domain family upon which ligand
(diamonds) and protein (grey ellipses) have been mapped. These
binding sites are mapped onto the ASTRAL alignment of the
family and the cumulative overlap of ligand and protein binding
positions is quantified. (C) The ligand binding sites are also
mapped directly onto individual protein interfaces, in this case the
interaction between domains A and B, and the overlap quantified.
(D) The distribution of function propensities (Text Eqn 5) for
significantly overlapping and non-overlapping families, as anno-
tated by SUPERFAMILY. Function propensities were considered
significant (asterisk) at the alpha = 0.05 level if the 95% confidence
interval estimated by bootstrap resampling did not include the
value 1 (Table S4). (E) Residue conservation of bi-functional
alignment positions. The number of amino acid types observed at
alignment positions that are involved in binding only ligands
(dashed; n = 46,610), only proteins (double dashed; n = 491,723),
or both proteins and ligands (black;n = 102,436). The distribution
for all solvent exposed residues (grey; n = 1,147,882) is shown for
comparison.
Found at: doi:10.1371/journal.pcbi.1000668.s008 (0.34 MB
TIF)
Figure S2 Maximum and cumulative ligand-protein binding site
overlap observed at protein–protein interactions as a function of
sequence identity. The maximum and cumulative observed ligand
binding site overlap (y-axis) for (A,G) inter-molecular, (B,H) intra-
molecular domain–domain, and (C,I) domain–peptide interac-
tions, as a function of the ligand binding site sequence identity (x-
axis). The densities in these plots are represented by colors that
range from yellow (no density) to blue (maximum density). The
overlap profiles are shown at minimum ligand binding site identity
thresholds of (D,J) 30%, (E,K) 50%, and (F,L) 90% for inter-
molecular (black), intra-molecular (orange) domain–domain, and
domain–peptide (cyan) interactions. Tick marks, arranged as ‘rug
plots’, represent interfaces of each type that exhibit a particular
level of interface coverage. The overlap score refers to the fraction
of interface residues aligned to ligand binding site residues (Text
Eqn 2).
Found at: doi:10.1371/journal.pcbi.1000668.s009 (1.87 MB TIF)
Acknowledgments
We thank Ursula Pieper and Andrea Rossi (UCSF) for maintenance of
LIGBASE, Jim Wells (UCSF) for valuable comments, and Goran Ceric for
managing HHMI Janelia’s high performance computing resources.
Author Contributions
Conceived and designed the experiments: FPD AS. Performed the
experiments: FPD. Analyzed the data: FPD AS. Wrote the paper: FPD AS.
References
1. Berg T (2003) Modulation of protein-protein interactions with small organic
molecules. Angew Chem Int Ed Engl 42: 2462–2481.
2. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug
discovery at protein-protein interfaces. Nature 450: 1001–1009.
3. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein
interactions: progressing towards the dream. Nat Rev Drug Discov 3: 301–317.
4. Jones S, Thornton JM (1996) Principles of protein-protein interactions. Proc
Natl Acad Sci U S A 93: 13–20.
5. Conte LL, Chothia C, Janin J (1999) The atomic structure of protein-protein
recognition sites. J Mol Biol 285: 2177–2198.
6. Caffrey DR, Somaroo S, Hughes JD, Mintseris J, Huang ES (2004) Are protein-
protein interfaces more conserved in sequence than the rest of the protein
surface? Protein Sci 13: 190–202.
7. Laskowski RA, Luscombe NM, Swindells MB, Thornton JM (1996) Protein
clefts in molecular recognition and function. Protein Sci 5: 2438–2452.
8. Clackson T, Wells JA (1995) A hot spot of binding energy in a hormone-receptor
interface. Science 267: 383–386.
9. Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol
Biol 280: 1–9.
10. Keskin O, Ma B, Nussinov R (2005) Hot regions in protein–protein interactions:
the organization and contribution of structurally conserved hot spot residues.
J Mol Biol 345: 1281–1294.
11. Thanos CD, DeLano WL, Wells JA (2006) Hot-spot mimicry of a cytokine
receptor by a small molecule. Proc Natl Acad Sci U S A 103: 15422–15427.
12. Arkin MR, Randal M, DeLano WL, Hyde J, Luong TN, et al. (2003) Binding of
small molecules to an adaptive protein-protein interface. Proc Natl Acad
Sci U S A 100: 1603–1608.
13. Eyrisch S, Helms V (2007) Transient pockets on protein surfaces involved in
protein-protein interaction. J Med Chem 50: 3457–3464.
14. Elber R, Karplus M (1987) Multiple conformational states of proteins: a
molecular dynamics analysis of myoglobin. Science 235: 318–321.
15. Qian B, Ortiz AR, Baker D (2004) Improvement of comparative model accuracy
by free-energy optimization along principal components of natural structural
variation. Proc Natl Acad Sci U S A 101: 15346–15351.
16. Leo-Macias A, Lopez-Romero P, Lupyan D, Zerbino D, Ortiz AR (2005) An
analysis of core deformations in protein superfamilies. Biophys J 88: 1291–1299.
17. Davis FP, Sali A (2005) Pibase: a comprehensive database of structurally defined
protein interfaces. Bioinformatics 21: 1901–1907.
18. Murzin AG, Brenner SE, Hubbard T, Chothia C (1995) Scop: a structural
classification of proteins database for the investigation of sequences and
structures. J Mol Biol 247: 536–540.
19. Stuart AC, Ilyin VA, Sali A (2002) Ligbase: a database of families of aligned
ligand binding sites in known protein sequences and structures. Bioinformatics
18: 200–201.
20. Chandonia JM, Hon G, Walker NS, Conte LL, Koehl P, et al. (2004) The astral
compendium in 2004. Nucleic Acids Res 32: D189–D192.
21. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of
spatial restraints. J Mol Biol 234: 779–815.
Overlapping Ligand and Protein Binding Sites
PLoS Computational Biology | www.ploscompbiol.org 9 February 2010 | Volume 6 | Issue 2 | e1000668
22. Wilson D, Pethica R, Zhou Y, Talbot C, Vogel C, et al. (2009) Superfamily–
sophisticated comparative genomics, data mining, visualization and phylogeny.
Nucleic Acids Res 37: D380–D386.
23. Ellis JJ, Broom M, Jones S (2007) Protein-rna interactions: structural analysis
and functional classes. Proteins 66: 903–911.
24. Erlanson DA, Wells JA, Braisted AC (2004) Tethering: fragment-based drug
discovery. Annu Rev Biophys Biomol Struct 33: 199–223.
25. Marti-Renom MA, Rossi A, Al-Shahrour F, Davis FP, Pieper U, et al. (2007)
The annolite and annolyze programs for comparative annotation of protein
structures. BMC Bioinformatics 8 Suppl 4: S4.
26. Crabtree GR, Schreiber SL (1996) Three-part inventions: intracellular signaling
and induced proximity. Trends Biochem Sci 21: 418–422.
27. Bhattacharyya RP, Remenyi A, Yeh BJ, Lim WA (2006) Domains, motifs, and
scaffolds: the role of modular interactions in the evolution and wiring of cell
signaling circuits. Annu Rev Biochem 75: 655–680.
28. Sokolskaja E, Sayah DM, Luban J (2004) Target cell cyclophilin a modulates
human immunodeficiency virus type 1 infectivity. J Virol 78: 12800–12808.
29. Sedrani R, Kallen J, Cabrejas LMM, Papageorgiou CD, Senia F, et al. (2003)
Sanglifehrin-cyclophilin interaction: degradation work, synthetic macrocyclic
analogues, x-ray crystal structure, and binding data. J Am Chem Soc 125:
3849–3859.
30. Howard BR, Vajdos FF, Li S, Sundquist WI, Hill CP (2003) Structural insights
into the catalytic mechanism of cyclophilin a. Nat Struct Biol 10: 475–481.
31. Wurtele M, Jelich-Ottmann C, Wittinghofer A, Oecking C (2003) Structural
view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO J 22:
987–994.
32. Bunney TD, Boer AHD, Levin M (2003) Fusicoccin signaling reveals 14-3-3
protein function as a novel step in left-right patterning during amphibian
embryogenesis. Development 130: 4847–4858.
33. Sanchez AM, Thomas D, Gillespie EJ, Damoiseaux R, Rogers J, et al. (2007)
Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob
Agents Chemother 51: 2403–2411.
34. Wang X, Li MX, Sykes BD (2002) Structure of the regulatory n-domain of
human cardiac troponin c in complex with human cardiac troponin i147-163
and bepridil. J Biol Chem 277: 31124–31133.
35. Drum CL, Yan SZ, Bard J, Shen YQ, Lu D, et al. (2002) Structural basis for the
activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 415:
396–402.
36. Higueruelo AP, Schreyer A, Bickerton GR, Pitt WR, Groom CR, et al. (2009)
Atomic interactions and profile of small molecules disrupting protein-protein
interfaces: the timbal database. Chem Biol Drug Des 74: 457–467.
37. Parthasarathi L, Casey F, Stein A, Aloy P, Shields DC (2008) Approved drug
mimics of short peptide ligands from protein interaction motifs. J Chem Inf
Model 48: 1943–1948.
38. Kleywegt GJ (1999) Recognition of spatial motifs in protein structures. J Mol
Biol 285: 1887–1897.
39. Zhu H, Sommer I, Lengauer T, Domingues FS (2008) Alignment of non-
covalent interactions at protein-protein interfaces. PLoS ONE 3: e1926.
40. Shulman-Peleg A, Shatsky M, Nussinov R, Wolfson HJ (2008) Multibind and
mappis: webservers for multiple alignment of protein 3d-binding sites and their
interactions. Nucleic Acids Res 36: W260–W264.
41. Ofran Y, Rost B (2007) Protein-protein interaction hotspots carved into
sequences. PLoS Comput Biol 3: e119.
42. Thorn KS, Bogan AA (2001) Asedb: a database of alanine mutations and their
effects on the free energy of binding in protein interactions. Bioinformatics 17:
284–285.
43. Kortemme T, Baker D (2002) A simple physical model for binding energy hot
spots in protein-protein complexes. Proc Natl Acad Sci U S A 99: 14116–14121.
44. Ma B, Elkayam T, Wolfson H, Nussinov R (2003) Protein-protein interactions:
structurally conserved residues distinguish between binding sites and exposed
protein surfaces. Proc Natl Acad Sci U S A 100: 5772–5777.
45. Kuriyan J, Eisenberg D (2007) The origin of protein interactions and allostery in
colocalization. Nature 450: 983–990.
46. Datta D, Scheer JM, Romanowski MJ, Wells JA (2008) An allosteric circuit in
caspase-1. J Mol Biol 381: 1157–1167.
47. Collins SR, Kemmeren P, Zhao XC, Greenblatt JF, Spencer F, et al. (2007)
Toward a comprehensive atlas of the physical interactome of saccharomyces
cerevisiae. Mol Cell Proteomics 6: 439–450.
48. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008)
Identification of host proteins required for hiv infection through a functional
genomic screen. Science 319: 921–926.
49. de Chassey B, Navratil V, Tafforeau L, Hiet MS, Aublin-Gex A, et al. (2008)
Hepatitis c virus infection protein network. Mol Syst Biol 4: 230.
50. Davis FP, Barkan DT, Eswar N, McKerrow JH, Sali A (2007) Host pathogen
protein interactions predicted by comparative modeling. Protein Sci 16:
2585–2596.
51. Dyer MD, Murali TM, Sobral BW (2008) The landscape of human proteins
interacting with viruses and other pathogens. PLoS Pathog 4: e32.
52. Projan SJ (2003) Why is big pharma getting out of antibacterial drug discovery?
Curr Opin Microbiol 6: 427–430.
53. Lebeis SL, Kalman D (2009) Aligning antimicrobial drug discovery with
complex and redundant host-pathogen interactions. Cell Host Microbe 5:
114–122.
54. Dimitropoulos D, Ionides J, Henrick K (2006) Using msdchem to search the pdb
ligand dictionary. Curr Protoc Bioinformatics Chapter 14: Unit14.3.
Overlapping Ligand and Protein Binding Sites
PLoS Computational Biology | www.ploscompbiol.org 10 February 2010 | Volume 6 | Issue 2 | e1000668
